First-in-human study of IPH4102 for relapsed cutaneous T-cell lymphoma

First-in-human study of IPH4102 for relapsed cutaneous T-cell lymphoma

VJHemOnc

1 year
184 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, on the progress of a new monoclonal antibody, IPH4102, being trialed for the first time in humans (NCT02593045). Prof. Bagot describes the results of the KIR3DL2-targeting antibody currently in Phase I of development, highlighting the plan to conduct the drug's Phase II clinical trial in 2019 on patients of Sézary syndrome, mycosis fungoides and nodal peripheral T-cell lymphoma.
Up Next Autoplay